Sarepta's Duchenne gene therapy misses main goal in study - TradingView

Reuters | Nov. 3, 2025, 4:22 p.m. | Original
Sarepta's Duchenne gene therapy misses main goal in study TradingView
Stocks end mixed as AI names keep Nasdaq, S&P afloat - TradingView Hims and Hers beats revenue estimates on strong subscriber growth - TradingView